Löschung
Seite 1 von 2 Neuester Beitrag: 19.06.17 08:20 | ||||
Eröffnet am: | 17.06.17 13:06 | von: Johiin | Anzahl Beiträge: | 44 |
Neuester Beitrag: | 19.06.17 08:20 | von: AnonymusNo. | Leser gesamt: | 15.616 |
Forum: | Hot-Stocks | Leser heute: | 14 | |
Bewertet mit: | ||||
Seite: < | 2 > |
Zeitpunkt: 19.06.17 08:21
Aktionen: Löschung des Beitrages, Thread geschlossen
Kommentar: Regelverstoß - Bitte vorhandeneb Thread zur Aktie nutzen.
Wenn doch will ich Quellen sehen. Keine Forum-Spekulationen in den USA.
Quellen bitte!
hierzu aber gerne einer zum anstehenden Reverse-Split !!!
Zitat:"The Annual Meeting has been adjourned until Friday, June 16, 2017 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 5, 2017, including a proposal to approve an amendment to its amended and restated certificate of incorporation to effect a reverse stock split of its common stock, which the Company believes is vitally important to the Company’s future. ......... THE COMPANY STRONGLY ADVISES ALL OF ITS STOCKHOLDERS TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS RELATING TO THE ANNUAL MEETING BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS ARE AVAILABLE AT NO CHARGE ON THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT WWW.SEC.GOV. In addition, copies of the Proxy Statement and other documents may be obtained free of charge by accessing the Company’s website at www.delcath.com or by contacting the Company’s Corporate Secretary at 212-489-2100 or by mail to Corporate Secretary, Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New York 10019... "ENDE Zitat
Source:https://www.stockwatch.com/News/...70605&symbol=DCTH®ion=U
Zitat:"
First Quarter Financial Results
Revenue for the three months ended March 31, 2017 was $0.74 million, an increase of 100% from $0.37 million for the prior year period. Selling, general and administrative expenses were approximately $2.4 million, unchanged from the prior year quarter. Research and development expenses for the current quarter increased to $2.3 million from $1.3 million in the prior year quarter. Total operating expenses for the current quarter were $4.7 million compared with $3.7 million in the prior year quarter.
The Company reported a net loss for the 2017 first quarter of $11.3 million, or $0.25 per share based on 45.1 million weighted average common shares outstanding, compared with a net loss in the prior year period of $1.8 million or $1.25 per share based on 1.5 million weighted average common shares outstanding. The increase is primarily due to an $8.4 million increase in interest expense primarily related to the amortization of debt discounts, a non-cash item, and a $1.0 million increase in operating expenses primarily related to increased investment in clinical trial initiatives. This was offset by a $0.4 million change in the fair value of the warrant liability, a non-cash item, and a $0.27 million improvement in gross profit due to higher sales.
Balance Sheet Highlights
As of March 31, 2017, Delcath had cash and cash equivalents of $6.4 million, compared with $4.4 million as of December 31, 2016. During the first quarter of 2017, the Company used $3.8 million of cash to fund operating activities. Delcath believes it has sufficient capital and access to committed capital to fund its operating activities through the end of 2017. " ENDE Zitat
Source:http://delcath.com/reuters-news/?id=2271263
Bin hier auch zw. 0.16 und 0.23 investiert und aktuell ist bei mir keine Euphorie.
Hier wird keine Rakete gezündet, bzw. sie kommt schnell wieder auf die Erde zurück. Bisher wurden Aktionäre hier nur abgezockt, schaut Euch an von wo die Aktie innerhalb eines Jahres kommt.